TABLE 2.
Clinical rhythm outcomes.
| Paroxysmal AF (n = 660) |
Persistent AF (n = 394) |
|||||
| Pre COVID-19 era | COVID-19 era | P-value | Pre COVID-19 era | COVID-19 era | P-value | |
| (n = 318) | (n = 342) | (n = 135) | (n = 259) | |||
| Follow-up months | 11 (7–15) | 12 (6–15) | 0.898 | 11 (7–15) | 11 (6–14) | 0.609 |
| Compliant to Holter monitoring | 235 (73.9) | 235 (68.7) | 0.166 | 90 (66.7) | 145 (56.0) | 0.052 |
| Post-ablation medication | ||||||
| ACEi, or ARB, n (%) | 105 (33.0) | 100 (29.2) | 0.335 | 43 (31.9) | 110 (42.5) | 0.052 |
| Beta blocker, n (%) | 134 (42.1) | 146 (42.7) | 0.949 | 79 (58.5) | 154 (59.5) | 0.942 |
| Statin, n (%) | 115 (36.2) | 144 (42.1) | 0.138 | 53 (39.3) | 123 (47.5) | 0.146 |
| AAD use | ||||||
| AADs at discharge, n (%) | 93 (29.2) | 76 (22.2) | 0.048 | 70 (51.9) | 95 (36.7) | 0.005 |
| AADs after 3 months, n (%) | 116 (36.5) | 87 (27.0) | 0.013 | 84 (62.2) | 106 (45.1) | 0.002 |
| AADs at final follow-up, n (%) | 92 (28.9) | 80 (25.2) | 0.326 | 65 (48.1) | 109 (47.4) | 0.975 |
| Early recurrence, n (%) | 80 (25.2) | 58 (17.0) | 0.013 | 73 (54.1) | 129 (49.8) | 0.485 |
| Recurrence type AF, n (% in early recur) | 72 (90.0) | 54 (93.1) | 0.739 | 68 (93.2) | 123 (95.3) | 0.735 |
| Recurrence type AT, n (% in early recur) | 8 (10.0) | 4 (6.9) | 5 (6.8) | 6 (4.7) | ||
| Late recurrence, n (%) | 54 (17.0) | 32 (9.4) | 0.005 | 29 (21.5) | 49 (18.9) | 0.636 |
| Recurrence type AF, n (% in recur) | 48 (88.9) | 29 (90.6) | 1.000 | 28 (96.6) | 48 (98.0) | 1.000 |
| Recurrence type AT, n (% in recur) | 6 (11.1) | 3 (9.4) | 1 (3.4) | 1 (2.0) | ||
| Cardioversion, n (% in recur) | 10 (18.5) | 1 (3.1) | 0.083 | 12 (41.4) | 12 (25.0) | 0.211 |
AAD, antiarrhythmic drug; ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; AT, atrial tachycardia; COVID-19, coronavirus disease 2019.